Clinical trials
Gastrointestinal Cancer Metastatic clinical trials
Below are recruiting gastrointestinal cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 420 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06121700RecruitingPhase 2
Chemoimmunotherapy and radiation before surgery for limited spread stomach cancer
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
ShanghaiAges 18–75 - NCT07869836RecruitingPhase 3
Comparing new drug to standard chemo for advanced bladder cancer
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
Macon, GeorgiaAges 18 years+ - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Orlando, FloridaAges 18 years+ - NCT07608848RecruitingEarly Phase 1
Imaging study of new cancer-targeting radioactive drugs
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
Perth, Western AustraliaAges 18 years+ - NCT07590934RecruitingPhase 1/Phase 2
Drug combination study for advanced prostate cancer
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
Duarte, CaliforniaAges 18–99 - NCT07529808RecruitingPhase 1/Phase 2
New Drug BHB810 for Advanced Stomach Cancer
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Duarte, CaliforniaAges 18 years+ - NCT07432295RecruitingPhase 2
Givastomig plus nivolumab and chemo for advanced stomach cancer
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Goodyear, ArizonaAges 18 years+ - NCT07418749RecruitingPhase 3
Testing a new drug for advanced cervical cancer after standard treatments
This trial is testing a new drug called SHR-A2102 against standard chemotherapy for people with advanced cervical cancer that has not responded to platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor). The goal is to see if the new drug works better and what side effects it may cause.
Guangzhou, GuangdongAges 18 years+ - NCT07315854RecruitingPhase 2
Immunotherapy combo plus chemo for untreated stomach cancer
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT06702995RecruitingPhase 1/Phase 2
Study of XNW5004 plus enzalutamide for advanced prostate cancer
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Jinan, ShandongAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT07107750RecruitingPhase 1
New drug combo for untreated advanced bile duct cancer
This trial tests a new targeted drug (emavusertib) combined with standard chemotherapy and immunotherapy for people with advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination is safe and effective.
St Louis, MissouriAges 18 years+ - NCT07056777RecruitingPhase 1/Phase 2
DR30206 plus standard therapy for advanced GI cancer
This trial tests a new drug called DR30206 combined with standard therapy for advanced gastrointestinal cancers. It may be an option if you have colorectal, esophageal, gastric, or gastroesophageal junction cancer and have had little or no prior chemotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07050394RecruitingEarly Phase 1
Experimental drug for advanced colorectal cancer
This trial tests a new experimental drug (HNF4α srRNA) given through a vein for people with advanced colorectal cancer that has not responded to or cannot be treated with standard therapies. The goal is to see if this treatment can help shrink or slow the growth of the cancer.
Shanghai, None SelectedAges 18 years+ - NCT07043608RecruitingPhase 2
Zanzalintinib for kidney cancer that spread to bone
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
San Francisco, CaliforniaAges 18 years+ - NCT07024173RecruitingPhase 3
HRS-8080 versus doctor's choice for advanced breast cancer
This trial tests a new medicine called HRS-8080 for locally advanced or metastatic breast cancer. It compares HRS-8080 with whatever treatment your doctor would normally choose for you.
Guangzhou, GuangdongAges 18–75 - NCT06959550RecruitingPhase 2
Ivonescimab for previously treated metastatic colorectal cancer
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Houston, TexasAges 18 years+ - NCT06889610RecruitingPhase 2
Ablation plus drug therapy for advanced solid tumors
This trial tests combining a liver tumor ablation procedure with systemic drugs for people with advanced colorectal, breast, or melanoma cancer that has spread to the liver. The goal is to see if this approach can help when standard treatments have stopped working.
ShanghaiAges 18–80 - NCT06298916RecruitingPhase 1/Phase 2
Study of 64Cu-LNTH-1363S in Sarcoma or GI Cancer
This trial tests a new imaging agent, 64Cu-LNTH-1363S, to see if it can find certain sarcomas and gastrointestinal cancers. The goal is to help doctors better see where your cancer is and plan the best treatment. You may be eligible if you have a sarcoma or a GI cancer and are willing to have a tumor tissue sample taken.
Duarte, CaliforniaAges 15 years+ - NCT06678269RecruitingPhase 1
Abemaciclib and radiation for metastatic breast cancer
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
Basking Ridge, New JerseyAges 18 years+ - NCT05406167Recruiting
Tracking quality of life during radiotherapy with a new system
This study collects information about how you feel and how treatment is delivered while you receive radiotherapy using the RefleXion Medical radiotherapy system. It may help doctors improve care and better understand what affects quality of life during treatment.
Duarte, CaliforniaAges Any age - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Chandler, ArizonaAges 18 years+ - NCT06420206Recruiting
Goals of care discussion in the ER for advanced cancer
This study is for people with advanced lung or GI cancer who come to the emergency room at MD Anderson. It’s testing a conversation to help you and your doctor discuss your goals and wishes for care.
Houston, TexasAges 18 years+ - NCT06008054RecruitingPhase 2
New drug combo for advanced gastrointestinal cancers
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Gastrointestinal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastrointestinal cancer metastatic?
- Yes. Clin2 currently lists 420 recruiting gastrointestinal cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastrointestinal cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastrointestinal cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.